Fortschritte in der Diagnose und Therapie von Erkrankungen der Augenoberfläche: Trockenes Auge und okuläre Allergien

Zusammenfassung

Auf dem jährlichen Treffen der „Association for Research in Vision and Ophthalmology” (ARVO) 2005 wurden neueste Forschungsergebnisse aus sämtlichen ophthalmologischen Disziplinen vorgestellt. Von besonderem Interesse war der aktuelle Forschungsstand in den Bereichen „trockenes Auge” und „okuläre Allergie”. Da diese beiden Erkrankungen häufig und aufgrund einer Reihe sich überschneidender Symptome oft schwer zu differenzieren sind, besteht Bedarf an schnelleren und genaueren Diagnosemethoden. Daher wurden zahlreiche neue Hilfsmittel vorgestellt, die in klinischen Studien, aber auch in der täglichen klinischen Praxis die Differenzialdiagnose zwischen trockenem Auge und okulärer Allergie erleichtern. Ein besseres Verständnis der molekularen Mechanismen in der Pathogenese dieser Krankheitsprozesse hat zudem zu neuen Behandlungsstrategien beim trockenen Auge und der okulären Allergie geführt.

Abstract

The 77^th meeting of the Association for Research in Vision and Ophthalmology (ARVO) presented the latest developments in clinical research and practice across a range of ophthalmic disciplines. Of particular interest was the current status of research in dry eye and ocular allergy. With these conditions being very common to ophthalmologists, and the fact that they are difficult to differentiate due to the number of overlapping symptoms, there remains a need for more rapid and accurate methods for their diagnosis. Therefore, a number of new tools were presented that have the potential for use in clinical trials and practice to improve the diagnosis and assessment of dry eye and ocular allergy. Some of these tools have been developed based on a greater understanding of the pathophysiology of dry eye and ocular allergy, and the various molecular pathways involved. Indeed, a greater understanding of the molecular mechanisms involved in the pathogenesis of dry eye and ocular allergy has identified potential targets for the treatment of these conditions. Continuing research into new agents can provide ophthalmologists with a number of options that will ultimately benefit the patient.

Trockenes Auge - okuläre Allergie

Dry eye syndrome - ocular allergy

Literatur

• 1 Araki H, Takamura E, Sinozaki K. et al .Th1/Th2 cytokine levels in the tear fluid of patients with Sjogren’s syndrome. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 2 Bazan H, Esquenazi S, Bui V. et al .Topical combination of NGF and DHA increases corneal nerve regeneration after PRK in rabbits. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 3 Bernstein P, Mitchell P, Nichols K. Reliability of grading lissamine green conjunctival staining. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 4 Bourcier T, Acosta M, Borderie V. et al .Decreased corneal sensitivity in dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 5 Calonge M, Corrales R M, Saez V. et al .Can ocular mucin gene levels be used as an investigational test for dry eye?. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 6 Casavani J, Ousler I II GW, Wilcox K A. et al .A correlation between the signs and symptoms of dry eye and the duration of dry eye diagnosis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 7 Christensen M T, Meadows D L, Stein J. et al .A comparison of performance between a new concept artificial tear and Systane lubricant eye drops. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 8 D’Arienzo P A, Granet D, Epstein A B. et al .Clinical efficacy of olopatadine and epinastine in allergic conjunctivitis subjects defined by sensitivity to sensitivity to conjunctival allergen challenge (CAC). Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 9 De Paiva C S, Corrales R M, Villareal A L. et al .Anti-inflammatory therapy preserves corneal barrier function in experimental murine dry eye. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 10 Dogru M, Okada N, Kato N A. et al .Tear function and ocular surface mucin alterations in atopic dermatitis patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 11 Donshik P C, Foulks G, Monica M. et al .Multicenter, randomized, double-masked, dose-response, placebo-controlled, parallel-group study of the safety and efficacy of rebamipide (OPC-12 759) sterile ophthalmic suspension in the treatment of dry eye. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 12 Dunn J P, Csaky K G, Kim H. et al .A novel episcleral cyclosporine implant for keratoconjunctivitis sicca. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 13 Elizondo A E, Di Pascuale M A, Gao Y Y. et al .Detection of blink related microtrauma by kinetic analysis of tear interference images in patients with Steven Johnson syndrome and toxic epidermal necrolysis syndrome. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 14 Fujitsu Y, Fukuda K, Kimura K. et al .Mitogenic and antiapoptotic effects of interleukin-4 or interleukin-13 in human conjunctival fibroblasts. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 15 Goto E, Dogru M, Matsumoto Y. et al .Topical eye ointment application to lid margin for the treatment of dry eye. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 16 Greiner J V, Glonek T, Scaffidi R. Evaluation of the first metastable lipid emulsion on symptomatic dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 17 Hamrah P, Jiang S, Sohn J H. et al .Evaluation of ocular surface staining with lissamine green. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 18 Herrygers L, Noecker R S. Efficacy of cyclosporine A (Restasis) for the treatment of dry eye symptoms in the first 30 days of therapy. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 19 Hida R Y, Ohashi Y, Dogru M. et al .Elevated levels of human a-defensin in the tears of patients with allergic conjunctival disease complicated by corneal lesions; detection by SELDI protein chip system and quantification. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 20 Jacob C, Ham B M, Keese M M. et al .Identification and comparison of phosphorylated lipids in normal and dry eye rabbit tears by MALDI-TOF MS. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 21 Kamoi M, Goto E, Dogru M. et al .Tear evaporation rates and lipid layer status in non-Sjogren syndrome aqueous tear deficiency dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 22 Kojima T, Hara S, Ishida R. et al .Clinical evaluation of new punctal plug (Smart PlugTM) for the treatment of dry eye patient that conventional plugs doesn’t suit. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 23 Kramann C A, Pfeiffer N. SELDI-TOF-MS protein chip array profiling of tears from dry-eye patients: diagnostic applications of new protein biomarkers. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 24 Kumagai N, Fukuda K, Nishida T. Enhancement of conjunctival inflammation by corneal epithelial ablation in experimental allergic conjunctivitis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 25 Labetoulle M, Mariette X, Tick S. et al .Optimization of the phenol red thread for assessment of ocular dryness in Sjogren’s syndrome. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 26 Leonardi A A, Brun P, DiStefano A. et al .Differential expression of matrix metalloproteinases in vernal keratoconjunctivitis, allergic asthma and nasal polyps. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 27 Mastromarino A, Papadia M, Amico V. et al .The effect of medium chain triglycerides-containing tear substitute on the dynamics of lipid layer interference patterns (DLIP) in dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 28 Micera A, Lambiase A, Lovieno A. et al .Nerve growth factor (NGF) modulates tissue remodeling in vernal keratoconjunctivitis (VKC). Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 29 Nichols K, Young L, Green-Church K B. et al .Assessment of meibomain lipids in postmenopausal women using electrospray ionization mass spectrometry. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 30 Ogawa Y, Dogru M, Ishida R. et al .Capillary meniscometry (CM): a new and simple concept of tear meniscus evaluation. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 31 Oliva A M, Slonim C B. Patient evaluation of azelastine HCl versus olopatadine HCl in the treatment of allergic conjunctivitis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 32 Ousler I II GW, Haque R, Weichselberger A. et al .Comparison of pimecrolimus 1 %, 0.3 % and 0.1 % with vehicle for the treatment of dry eye in the controlled adverse environment (CAE) model. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 33 Pascuale E A, Gao Y Y, Baradaran-Rafti A. et al .The tear film breaks up from the lipid tear film by condensation: evidence provided by kinetic tear interference analysis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 34 Rao S N. Comparison of the efficacy of topical cyclosporine 0.05 % compound with Tobradex for the treatment of posterior blephartis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 35 Robert C W, Carnigila P E, Brazzo B G. Comparison of cyclosporine to punctal plugs in relieving the signs and symptoms of dry eyes. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 36 Rolando M, Mastromarino A, Barabino S. The dynamic lipid interference pattern (DILP) test in normal and dry eyes. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 37 Sack R A, Conradi L, Sathe S. et al .Antibody array analysis of the distribution of angiogenic modulators, growth factors, MMPs and TH-1/TH-2 cytokines in normal and pathological tears. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 38 Saiki M, Goto E, Asano-Kato N. et al .Kinetic analysis of tear lipid interference images in dry eye with allergic conjunctivitis. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 39 Sakimoto T, Shoji J, Ikeda A. et al .Active form of gelatinase in the tear fluid of recurrent corneal erosion patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 40 Scaffidi R, Korb D R, Greiner J V. et al .Lipid layer thickness and dry eyes symptoms. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 41 Schaberg A, Durham T, Kuhn K L. et al .Observations of worst symptom reporting among subjects with dry eye disease. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 42 Schechter B A, Wittpenn J R. Evaluation of ketorolac (Acular LS) during the induction phase of cyclosporine A (Restasis) therapy to improve patient comfort. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 43 Smolek M K, Yee R W, Khattak A. et al .Non-contact confocal microscopy of the tear film and ocular surface of normal and dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 44 Sundarraj C V, Foulks G N. Managing symptoms of allergy and dry eye in patients with keratoconus. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 45 Terauchi N, Goto E, Dogru M. et al .Tear film lipid layer observations in dry eye associated with visual display terminal work. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 46 Tomsic M, Gekkieva M, Weichselberger A. et al .Evaluation of pimecrolimus tablets 30 mg bid for the treatment of dry eye in primary Sjogren’s syndrome patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 47 Uchida A, Goto E, Dogru M. et al .Non-invasive interference tear meniscometry using tearscope-plus in dry eye patients. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 48 Uchino M, Goto E, Matsumoto Y. et al .Changes in tear evaporation rates after topical low-dose lipid eye ointment application to lid margin. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 49 Uchiyama E, Aronwicz J D, Shine W. et al .Relationship between vital staining and tear parameters in patients with KCS. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 50 Urashima H, Aoki A, Fujita K. et al .Pre-clinical studies of OPC-12 759 ophthalmic suspension for dry eye treatment. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 51 Vehige J G, Simmons P A, Carlise-Wilcox C. Assessment of signs and symptoms of dry eye after treatment with emulsion-based eye drops. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 52 Wang J, Aquaavella J, Zhao Z. et al .Simultaneous and real-time measurements of dynamic tear film thickness and upper and lower tear menisci. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005
• 53 Yoon K C, Song B Y, Seo M S. et al .Analysis of essential tear components in umbilical cord serum and its application for the treatment of ocular surface disease. Fort Lauderdale, Florida; 77. Jahrestreffen der ARVO 1. - 5.5.2005